Clinical Trials Logo

Stroke, Acute clinical trials

View clinical trials related to Stroke, Acute.

Filter by:

NCT ID: NCT03767842 Recruiting - Stroke, Acute Clinical Trials

Volumetric Impedance to Guide Stroke Response

VIGOR
Start date: July 18, 2018
Phase:
Study type: Observational

Assess the ability of the Visor System to detect hemispheric bioimpedance asymmetry

NCT ID: NCT03763929 Not yet recruiting - Stroke, Acute Clinical Trials

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

PHAST-TSC
Start date: March 1, 2019
Phase: Phase 2
Study type: Interventional

This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.

NCT ID: NCT03759938 Not yet recruiting - Atrial Fibrillation Clinical Trials

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial

OPTIMAS
Start date: February 1, 2019
Phase: Phase 4
Study type: Interventional

OPTIMAS is a large, phase IV, prospective, partially blinded randomised controlled trial of early (within ≤4 days [96hrs]) or standard (between day 7 and day 14 after stroke onset) initiation of anticoagulation after stroke in patients with atrial fibrillation (AF), using any licensed dose of a direct oral anticoagulant (DOAC). The trial will use a non-inferiority gatekeeper approach to test for non-inferiority of early anticoagulation followed by a test for superiority, if non-inferiority is established.

NCT ID: NCT03741400 Recruiting - Stroke, Acute Clinical Trials

Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke

vREHAB
Start date: October 1, 2018
Phase: N/A
Study type: Interventional

The Virtual Reality Glove for Hand and Arm Rehabilitation (vREHAB) trial is a randomized, controlled, phase 3 trial aiming to evaluate the safety, usability, and efficacy of a virtual reality biofeedback system (Neofect RAPAEL Smart Glove) to promote recovery of distal arm and hand function in the acute and subacute period after stroke, as compared to standard of care therapy. The aims of the study is to demonstrate: 1. the effect of Smart Glove use on functional recovery, in addition to standard of care rehabilitation therapy. 2. the feasibility of increasing the dose of rehabilitation in acute stroke patients with the Smart Glove. 3. the effect of Smart Glove use on quality of life.

NCT ID: NCT03733431 Not yet recruiting - Stroke Clinical Trials

Non-invasive TRanscutaneous Cervical Vagus Nerve Stimulation as a Treatment for Acute Stroke; Safety and Feasibility Study

TR-VENUS
Start date: December 2018
Phase: N/A
Study type: Interventional

This study aims to determine safety and feasibility of non-invasive transcutaneous cervical Vagus nerve stimulation (nVNS) when delivered promptly after clinical diagnosis of acute stroke. Vagus nerve stimulation will be performed via GammaCore® device. A total of 60 patients will be randomized to each of 3 different groups; 'standard dose' vagal stimulation, 'high dose' vagal stimulation, and 'sham stimulation' (1:1:1 ratio). Adverse device events, serious adverse device events, and feasibility of vagal nerve stimulation at the setting of acute stroke will be evaluated. The study will be performed in a multi-center fashion among stroke centers within TurkStrokeNet Network.

NCT ID: NCT03723382 Recruiting - Stroke, Acute Clinical Trials

Stroke in Egyptian Clinical REgisTry

SECRET
Start date: May 20, 2018
Phase:
Study type: Observational [Patient Registry]

This is a multi-institutional registry database for the patients with stroke and cerebrovascular diseases. Stroke is the second leading cause of death in the Egypt. Despite extensive research, most of the patients die or suffer from varying degree of post-stroke disabilities due to neurologic deficits. This registry aims to understand the disease and examine the disease dynamics at the National Level. additionally it aim to introduce an objective method for classifying the registered hospital on a spectrum of 6 level coded with colors (from Black to Green ) according the availability of the predetermined 5 bundles of services presented for patient

NCT ID: NCT03696121 Not yet recruiting - Stroke, Acute Clinical Trials

Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage

DASH
Start date: October 1, 2018
Phase: Phase 2
Study type: Interventional

Haemorrhagic stroke, an emergency caused by bleeding in the brain, often leads to death or long-term disability. A quarter of these patients are taking blood-thinning drugs (antiplatelet drugs, such as aspirin) because they are at risk of a heart attack or ischaemic stroke. Patients taking these drugs are more likely to die or be disabled if they have a haemorrhagic stroke. At present, there is no effective treatment for reversing their effects. Desmopressin is a drug which may reverse the effects of antiplatelet drugs and stop bleeding. The investigators would like to run a large randomised trial to see if Desmopressin can reduce the number of people who die or are disabled after haemorrhagic stroke.

NCT ID: NCT03679637 Recruiting - Stroke, Acute Clinical Trials

Tablet-based Aphasia Therapy in the Acute Phase After Stroke

Start date: September 28, 2018
Phase: N/A
Study type: Interventional

As aphasia is one of the most common and disabling disorders following stroke, in many cases resolving in long-term deficits, it is now thought that intensive aphasia therapy is effective, even in the chronic phase following stroke. However, as intensive aphasia rehabilitation is difficult to achieve in clinical practice, tablet-based aphasia therapies are explored to further facilitate language recovery. Although there is mounting evidence that computer-based treatments are effective, it is also important to assess the feasibility, usability and acceptability of these technologies, especially in the acute phase post stroke. The investigators assume that tablet-based aphasia therapy is a feasible treatment option for patients with aphasia in the acute phase following stroke. The researchers also believe that the specific app that will be used in therapy is user-friendly and that it will be well accepted by this specific patient population.

NCT ID: NCT03670862 Recruiting - Stroke, Acute Clinical Trials

Prediction Model for Recanalization Outcome Evaluation of Ischemic Stroke Using Multimodal CT

Start date: October 1, 2018
Phase:
Study type: Observational [Patient Registry]

To assess the effect of novel imaging biomarkers/ imaging patterns based on multi-model CT on patients selection/stratification for therapy decision support in large vessel acute ischemic stroke

NCT ID: NCT03662750 Recruiting - Stroke, Acute Clinical Trials

TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort

Start date: August 31, 2017
Phase: N/A
Study type: Interventional

DESIGN: exploratory, prospective, natural history, imaging cohort study BACKGROUND: Stroke causes a strong inflammatory response in the brain which is thought to contribute to permanent brain damage in stroke patients. To develop new therapies targeting inflammation we need to better understand how inflammation affects the injured brain tissue and how it relates to neurological deficits that directly affect the patients' quality of life. AIMS: To track the extent and location of inflammation in the brain after stroke over a period of 90 days. The study will explore whether the most inflamed areas in the brain undergo the most damage after stroke and correspond to the cognitive and neurological deficits experienced by stroke patients. METHODS: The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode. Patients will undergo: 1. Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain), 2. Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium), 3. Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning), 4. Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker). Venous cannula will be inserted into the forearm for the duration of the scans. POPULATION: 15- 25 patients (recruitment will cease once 15 patients have completed the study) ELIGIBILITY: Male and female stroke patients, aged 18-85, with a recent (within last 10 days) ischemic stroke of moderate severity, able and willing to provide informed consent LOCATION: Patients will be recruited at the Charing Cross Hospital, Imperial College Healthcare NHS Trust, and study scans will be performed by Invicro Centre for Imaging Sciences, Hammersmith Hospital DURATION: 18 months FUNDED BY: Biogen Idec Ltd